autologous anti-CD19 T-cell receptor fusion construct T cells TC-110

{
  "id": "MLC-T-ONC-011376",
  "term": "autologous anti-CD19 T-cell receptor fusion construct T cells TC-110",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, the autologous anti-CD19 TCR fusion construct (TRuC) T cells TC-110 specifically target and bind to CD19-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. Compared to chimeric antigen receptor (CAR) T cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy.",
  "synonyms": [
    "autologous anti-CD19 TRuC T cells TC-110",
    "CD19-specific epsilon-TRuC TC-110",
    "CD19-specific T-cell receptor fusion construct T cell TC-110",
    "TC 110 T cells",
    "TC-110 T cells",
    "TRuC T cells TC-110",
    "TRuC-T-cell-targeting CD19 TC-110"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-t-cell-receptor-fusion-construct-t-cells-tc-110/"
}